Lixivaptan

DB06666InvestigationalSmall molecule

Investigated for use/treatment in hyponatremia and congestive heart failure.

Chemical structure of Lixivaptan
Mechanism
Curator reviewed
Primary indication
Investigated for use/treatment in hyponatremia and congestive heart failure.Curator reviewed
Formula / weight
C27H21ClFN3O2 · 473.93 g/mol (avg)
Code names
CRTX-080 · VPA-985 · WAY-VPA-985

Resolves to

Compound
UNII8F5X4B082ECAS168079-32-1ChEMBLCHEMBL49429
Structure
InChIKeyPPHTXRNHTVLQED-UHFFFAOYSA-NSMILESCC1=CC=C(F)C=C1C(=O)NC1=CC=C(C(=O)N2CC3=CC=CN3CC3=C2C=CC=C3)C(Cl)=C1
Targets
P30518AVPR2P19113HDC

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
10Clinical trialsPhase, status and sponsor resolved per trial
Sign in
8+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Lixivaptan, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In